Company Filing History:
Years Active: 2022-2024
Title: Inventor Profile: Jakob Louris Feitsma
Introduction
Jakob Louris Feitsma is an esteemed inventor based in Utrecht, Netherlands. He has made significant contributions to the field of pharmaceutical sciences through his innovative work at Janssen Pharmaceuticals, Inc. With a total of three patents to his name, Feitsma has focused on advancing medical treatments that leverage the properties of polypeptides.
Latest Patents
Feitsma's latest patents revolve around the FimH lectin domain. One of his notable inventions is the "FimH mutant, compositions therewith and use thereof," which describes polypeptides comprising a FimH lectin domain with amino acid mutations that induce a low affinity conformation for mannose. This breakthrough has been pivotal in creating pharmaceutical compositions aimed at stimulating immune responses in subjects needing intervention. Furthermore, another patent details similar FimH mutants and their applicable methods in the same context, reinforcing Feitsma's ongoing commitment to enhancing therapeutic strategies.
Career Highlights
At Janssen Pharmaceuticals, Inc., Feitsma has been instrumental in developing groundbreaking pharmaceutical innovations. His expertise in protein engineering and immunology has allowed him to contribute to pivotal research efforts that aim at revolutionizing treatment methodologies.
Collaborations
Feitsma collaborates closely with talented colleagues, including Jan Grijpstra and Marleen Eveline Weerdenburg. Together, they work on innovative projects that push the boundaries of current pharmaceutical technologies, leading to significant advancements in immunity and therapeutic applications.
Conclusion
Jakob Louris Feitsma’s contributions as an inventor have not only added to the body of knowledge in pharmaceuticals but have also dedicatedly targeted the enhancement of health outcomes through innovative treatments. His work continues to inspire the field, and his patents represent crucial advancements that can influence the future of medicine.